Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIOSIG TECHNOLOGIES, INC.

(BSGM)
  Report
Delayed Nasdaq  -  04:00 2022-09-23 pm EDT
0.7300 USD   +6.10%
09/22BIOSIG TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
09/22BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
GL
09/22BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/19/2022 09/20/2022 09/21/2022 09/22/2022 09/23/2022 Date
0.75(c) 0.725(c) 0.71(c) 0.688(c) 0.73(c) Last
296 717 370 659 224 095 107 961 151 363 Volume
-8.54% -3.33% -2.07% -3.10% +6.10% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 1,29 M - -
Net income 2022 -26,1 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,18x
Yield 2022 -
Sales 2023 7,40 M - -
Net income 2023 -22,8 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,71x
Yield 2023 -
Capitalization 32,7 M 32,7 M -
Capi. / Sales 2022 25,4x
Capi. / Sales 2023 4,42x
Nbr of Employees 50
Free-Float 88,9%
More Financials
Company
BioSig Technologies, Inc. is a medical technology company. The Company is focused on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The Company is commercializing its PURE EP System, which is designed to address long-standing limitations that slow and... 
More about the company
Ratings of BioSig Technologies, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about BIOSIG TECHNOLOGIES, INC.
09/22BIOSIG TECHNOLOGIES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
AQ
09/22BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
GL
09/22BioSig Launches PURE EP™ Software Version 6 with ACCUVIZ™ Module
AQ
09/22BioSig Technologies, Inc. Launches PURE EP™ Software Version 6 with ACCUVIZ™ ..
CI
09/19BIOSIG TECHNOLOGIES, INC.(NASDAQCM : BSGM) dropped from S&P Global BMI Index
CI
09/16Taglich Brothers Initiates Coverage of BioSig Technologies, Inc.
AQ
09/09BIOSIG TECHNOLOGIES, INC. : Changes in Registrant's Certifying Accountant, Financial State..
AQ
09/06BIOSIG TECHNOLOGIES, INC. : Other Events (form 8-K)
AQ
08/30BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to S..
GL
08/30BioSig Strengthens Marketing and Sales Teams, Appoints National Account Executives to S..
AQ
08/24BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading..
GL
08/24BioSig Places Second PURE EP™ System For Evaluation at Cleveland Clinic a Leading..
AQ
08/24BioSig Technologies, Inc Places Second PURE EP™ System For Evaluation at Cleveland..
CI
08/17BioSig's Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhyth..
GL
08/17BioSig's Cardiac Signal Processing Technology To Be Featured at Kansas City Heart Rhyth..
AQ
More news
News in other languages on BIOSIG TECHNOLOGIES, INC.
09/22BioSig Technologies, Inc. Lance la version 6 du logiciel PURE EP׫ ; avec le module..
08/24BioSig Technologies, Inc. place le deuxième système PURE EP㬱 ; pour évaluation à ..
08/16BioSig Technologies prévoit une adoption accrue du système PURE EP
08/15BioSig Technologies, Inc. annonce ses résultats pour le deuxième trimestre et le semest..
07/07BioSig Technologies conclut un accord pour fournir une technologie médicale à l'Institu..
More news
Chart BIOSIG TECHNOLOGIES, INC.
Duration : Period :
BioSig Technologies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOSIG TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,73 $
Average target price 4,17 $
Spread / Average Target 471%
EPS Revisions
Managers and Directors
Kenneth L. Londoner Executive Chairman & Chief Executive Officer
Steven Chaussy Chief Financial Officer
Budimir S. Drakulic Chief Scientist
Zachary Koch Clinical Director
Lora Mikolaitis Vice President-Administration
Sector and Competitors